The post UnitedHealth Group releases results of independent audit appeared on BitcoinEthereumNews.com. UnitedHealthcare sign is displayed at its office buildingThe post UnitedHealth Group releases results of independent audit appeared on BitcoinEthereumNews.com. UnitedHealthcare sign is displayed at its office building

UnitedHealth Group releases results of independent audit

UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025.

Tim Evans | Reuters

UnitedHealth Group on Friday released the first results from a sprawling independent audit of its business practices and committed to a wide range of steps to track and implement improvements in three specific areas.

The health-care giant said it has adopted 23 ongoing “action plans” to put in place and monitor recommended improvements, with oversight by its internal audit and advisory services team. Around 65% of those actions will be complete by the end of 2025, while 100% of those plans will be finished by the end of March next year. 

The results come as private insurers try to rebuild trust with the American public after fierce, pent-up backlash over their practices and the broader U.S. health-care system. Critics say insurer business tactics have made it harder for some patients to access and pay for care. The company owns UnitedHealthcare, the nation’s largest and most powerful insurer. 

While the announcement on Friday is a step toward improving the business, it’s unclear how much it will change the public’s view on the company and the broader industry.

UnitedHealth in July announced that two independent consultancies had launched a third-party review of its business policies and performance metrics. That same day, UnitedHealth also confirmed that it is facing Department of Justice investigations over its Medicare billing practices. 

The independent audit marked one of Steve Hemsley’s earliest steps as CEO after he took the reins in May, following the abrupt departure of Andrew Witty.

“We hope that you see these assessments as a commitment to setting a new standard of transparency for the health care marketplace, as we believe that you and every person who engages with our health system deserves to understand how we go about our work,” Hemsley said in a letter Friday. 

“We know that our actions and decisions have significant impacts on patients, care providers and the broader health system, and we are determined to hold ourselves to the highest standard,” he added.

FTI Consulting reviewed UnitedHealthcare’s approaches to risk assessment operations within its Medicare Advantage programs, which refers to how the company rates the health status of members in those privately run plans. The firm also examined the company’s care services management policies, procedures and processes. 

Consulting firm the Analysis Group also assessed the policies and processes of Optum Rx – the company’s pharmacy benefit manager, or PBM  – for ensuring prescription discounts from drug manufacturers are “accurately collected and distributed to clients.” PBMs are middlemen who negotiate rebates with drug manufacturers on behalf of insurers, create lists of medications covered by insurance and reimburse pharmacies for prescriptions.

Hemsley said the firms determined that the company’s policies and practices are “robust, rigorous and generally sound; and, in many respects, industry leading.” But he noted that they also provided recommendations for improvements. 

For example, a review by the Analysis Group found that OptumRx has “implemented a comprehensive and well-structured framework that governs all stages of manufacturer discount administration.” 

More CNBC health coverage

The assessment identified at least 25 distinct “controls” in place that collectively lower the risk of miscalculating or delaying the distribution of discounts owed to clients and collecting incomplete discounts from drugmakers, said Aaron Yeater, managing principal at the Boston office of Analysis Group, in a document Friday. 

The review found “no deficiencies or need for corrective measures” but recommended ways to enhance Optum Rx’s practices. That includes strengthening Optum Rx’s escalation processes for resolving nonpayment and dispute cases through communication with manufacturers. Among UnitedHealth’s action plans is to develop a formal policy that supports procedures for addressing those cases. 

Yeater noted that he examined the business processes and not the legal and regulatory issues the company is facing with its PBM.

Meanwhile, FTI Consulting found that UnitedHealth scored better than its peers by several measures when it came to Medicaid and Medicare. But the firm pointed to slow decision-making on authorizations, documentation issues and the need to better address the findings raised in regulatory audits.

Beyond these first results, UnitedHealth said it will share the findings from a review of medical records of diagnosis codes during the first quarter. The company will also report on its processes to craft what it calls “evidence-based medical policy” by the middle of the year. 

Shares of UnitedHealth Group are down more than 35% for the year after it suspended its 2025 forecast amid skyrocketing medical costs, announced the surprise exit of Witty and grappled with the probes into its Medicare Advantage business. It followed a difficult 2024 marked by a historic cyberattack and public blowback after the murder of UnitedHealthcare’s CEO, Brian Thompson.

Correction: UnitedHealth Group had a difficult 2024. An earlier version misstated the year.

Source: https://www.cnbc.com/2025/12/19/unitedhealth-group-results-independent-audit-investigation.html

Market Opportunity
Sign Logo
Sign Price(SIGN)
$0.03479
$0.03479$0.03479
+0.60%
USD
Sign (SIGN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Unlocking Opportunities: Coinbase Derivative Blends Crypto ETFs and Tech Giants

Unlocking Opportunities: Coinbase Derivative Blends Crypto ETFs and Tech Giants

BitcoinWorld Unlocking Opportunities: Coinbase Derivative Blends Crypto ETFs and Tech Giants The financial world is constantly evolving, and a groundbreaking development has just arrived for investors seeking diversified exposure. Coinbase, a leading cryptocurrency exchange, has introduced an innovative Coinbase derivative product that’s poised to redefine investment strategies. This new offering uniquely combines crypto exchange-traded funds (ETFs) with the stability and growth potential of major U.S. technology stocks. What is This Revolutionary Coinbase Derivative? Coinbase’s latest financial innovation is a derivative product designed to track the performance of two powerful market segments. It’s a game-changer because it offers something unprecedented in the U.S. market. It tracks the “Magnificent Seven,” a group of seven dominant U.S. tech companies known for their significant market influence. It also includes BlackRock’s spot Bitcoin and Ethereum ETFs, providing direct exposure to the two largest cryptocurrencies. Additionally, Coinbase’s own stock is part of this unique blend, adding another layer of exposure to the crypto ecosystem. This Coinbase derivative marks the first time a U.S.-listed product has offered direct spot exposure to both cryptocurrencies and major equities in a single package. This simplifies investment, bridging traditional finance and digital assets. Bridging the Gap: Benefits for Investors with Coinbase Derivative This new Coinbase derivative offers several compelling advantages for both seasoned and new investors looking to diversify their portfolios efficiently. Simplified Diversification: Instead of managing separate investments, investors gain exposure to both through a single product, streamlining the process. Enhanced Accessibility: For those hesitant to directly invest in cryptocurrencies, this derivative provides a regulated and more familiar pathway through an established exchange. Potential for Growth: By combining high-growth tech companies with the dynamic potential of cryptocurrencies, the product aims to capture upside from both sectors. Innovation in Finance: It integrates digital assets into mainstream financial products, reflecting evolving global markets. This product caters to a growing demand for integrated investment solutions that reflect the interconnectedness of today’s financial world. Understanding the Components: Tech Giants and Crypto ETFs in the Coinbase Derivative To appreciate this Coinbase derivative, understanding its core components is essential. The “Magnificent Seven” refers to tech powerhouses driving significant market growth. On the cryptocurrency side, BlackRock’s spot Bitcoin and Ethereum ETFs are crucial. These ETFs allow investors to gain exposure to the price movements of Bitcoin and Ethereum without directly owning the underlying digital assets. This eliminates some complexities associated with crypto custody and security. The inclusion of Coinbase’s own stock further aligns the derivative with the crypto industry’s performance. This combination provides a balanced, dynamic investment profile, capturing modern market trends. Navigating the Future: Challenges and Considerations for the Coinbase Derivative While the Coinbase derivative presents exciting opportunities, investors should also be aware of potential challenges and considerations. All investments carry risks. Market Volatility: Cryptocurrencies are known for their price fluctuations, which can impact the derivative’s performance. Even large-cap tech stocks can experience significant swings. Regulatory Landscape: The regulatory environment for cryptocurrencies is still evolving. Changes could influence the value and availability of such products. Concentration Risk: While diversified across two asset classes, the product is still concentrated in specific tech companies and two main cryptocurrencies. Understanding these factors is crucial for informed decisions. Thorough research and considering risk tolerance are paramount before engaging. Coinbase’s introduction of this unique derivative product marks a significant milestone in the financial industry. By ingeniously blending the world of leading technology stocks with the dynamic growth of spot crypto ETFs, it offers investors an unprecedented avenue for diversified exposure. This move not only simplifies access to complex markets but also underscores the growing convergence of traditional finance and digital assets. It’s an exciting time to witness such innovation, providing new tools for portfolio expansion and risk management in an ever-changing economic landscape. Frequently Asked Questions About the Coinbase Derivative Here are some common questions about this new investment product: Q1: What exactly is the Coinbase derivative? A1: It’s a new financial product launched by Coinbase that tracks the performance of both major U.S. technology stocks (the Magnificent Seven) and spot Bitcoin and Ethereum ETFs, along with Coinbase’s own stock. Q2: Why is this derivative considered unique? A2: It’s the first U.S.-listed derivative to offer direct spot exposure to both cryptocurrencies and major equities within a single product, simplifying diversification for investors. Q3: Which specific tech companies are included in the “Magnificent Seven”? A3: While the exact composition can vary slightly depending on the index, it generally refers to leading U.S. tech giants like Apple, Microsoft, Amazon, Google (Alphabet), Meta, Nvidia, and Tesla. Q4: How does this product provide exposure to cryptocurrencies? A4: It achieves this through BlackRock’s spot Bitcoin and Ethereum ETFs, which allow investors to gain exposure to the price movements of these cryptocurrencies without directly holding the digital assets themselves. Q5: What are the main benefits of investing in this Coinbase derivative? A5: Key benefits include simplified diversification across tech and crypto, enhanced accessibility to digital assets, and the potential for growth from two dynamic market sectors. What are your thoughts on this innovative blend of crypto and tech? Share this article with your network and join the conversation about the future of diversified investing! To learn more about the latest explore our article on key developments shaping crypto market institutional adoption. This post Unlocking Opportunities: Coinbase Derivative Blends Crypto ETFs and Tech Giants first appeared on BitcoinWorld.
Share
Coinstats2025/09/23 05:10
Crossmint Partners with MoneyGram for USDC Remittances in Colombia

Crossmint Partners with MoneyGram for USDC Remittances in Colombia

TLDR Crossmint enables MoneyGram’s new stablecoin payment app for cross-border transfers. The new app allows USDC transfers from the US to Colombia, boosting financial inclusion. MoneyGram offers USDC savings and Visa-linked spending for Colombian users. The collaboration simplifies cross-border payments with enterprise-grade blockchain tech. MoneyGram, a global leader in remittance services, launched its stablecoin-powered cross-border [...] The post Crossmint Partners with MoneyGram for USDC Remittances in Colombia appeared first on CoinCentral.
Share
Coincentral2025/09/18 21:02
Why Peter Brandt Says The US Crypto Bill Won’t Be A Game-Changer

Why Peter Brandt Says The US Crypto Bill Won’t Be A Game-Changer

The post Why Peter Brandt Says The US Crypto Bill Won’t Be A Game-Changer appeared on BitcoinEthereumNews.com. Will a landmark US crypto bill send Bitcoin soaring
Share
BitcoinEthereumNews2025/12/20 08:21